PubMed Health⌕ Search

Biomedical subjects

J T Golay

Publications and source records attributed to J T Golay.

4 recordsLinked to original sources
PubMed1987

Pathways of human B-lymphocyte activation blocked by B-cell specific monoclonal antibodies.

The data presented in this report demonstrate that antibodies directed against B-cell specific surface antigens can block different modes of B-cell activation. The anti-CD 19 antibody HD37 strongly blocks the stimulation of thymidine incorporation induced by anti-mu and MLR supernatant and also partially inhibits the growth of long-term EBV-transformed cell lines. The anti-CD20 antibody B1, on the other hand, has little effect on anti-mu activation but prevents the stimulation of thymidine incorporation and transformation by EBV. We conclude that different mechanisms operate during B-cell activation by anti-mu and EBV involving different B-cell surface molecules.

Antibodies, Anti-Idiotypic↗
PubMed1986

B cells in patients with X-linked and 'common variable' hypogammaglobulinaemia.

E- cells from three patients with X-linked and three patients with non-familial 'common variable' hypogammaglobulinaemia were stained by indirect immunofluorescence with a panel of B cell specific monoclonal antibodies (anti-Bp95, Bp35 and Bp135). The number of B cells detected with the pan-B cell antibodies was variable between patients. One patient in each group was found to have near normal numbers of circulating B cells although those of the X-linked patient were clearly immature.

Adolescent↗
PubMed1985

The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.

Two monoclonal antibodies, 1F5 and B1, directed against the CD20 (Bp35) antigen were found to have both stimulatory and inhibitory effects on B cells. 1F5, but not B1, induces small resting tonsillar B cells and prolymphocytic leukemia cells to enlarge, to rapidly increase their RNA synthesis, and to become responsive to growth factors present in mixed lymphocyte reaction supernatants. In addition, 1F5 induces a moderate increase in thymidine uptake, which is accompanied by enhanced viability of the cells, but not by any increase in total cell number or by any detectable entry into S phase or mitosis. Taken together, these observations suggest that 1F5 can initiate transition from the G0 to the G1 phase of the cell cycle. The fact that all the changes observed can be inhibited by low concentrations (I50 = 50 ng/ml) of cyclosporin A is further evidence that 1F5 is involved at an early stage of B cell activation. Because both 1F5 and B1 belong to the IgG2a subclass, differences in their activities are likely to reflect their different epitope specificities. Although only 1F5 had stimulatory activity, both 1F5 and B1 strongly inhibited B cell differentiation to immunoglobulin secretion. Possible explanations for the dual activities of 1F5 and implications for the role of the CD20 antigen in B cell differentiation are discussed.

Animals↗